BRAF V600E mutation in papillary thyroid microcarcinoma: is it a predictor for the prognosis of patients with intermediate to high recurrence risk?

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J. Clin. 68 394-424

[2] Ferlay J(2009)“Aggressive papillary” thyroid microcarcinoma Eur. Arch. Otorhinolaryngol. 266 1959-1963

[3] Soerjomataram I(2014)Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up J. Clin. Endocrinol. Metab. 99 2834-2843

[4] Siegel RL(2015)American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer Thyroid 2016 1-133

[5] Torre LA(2005)BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer J. Clin. Endocrinol. Metab. 90 6373-6379

[6] Jemal A(2016)BRAF(V600E) is correlated with recurrence of papillary thyroid microcarcinoma: a systematic review, multi-institutional primary data analysis, and meta-analysis Thyroid 26 248-255

[7] Page C(2014)BRAF Clin. Nucl. Med 39 675-679

[8] Biet A(2016) mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma Eur. J. Nucl. Med Mol. Imaging 43 1034-1039

[9] Boute P(2020)Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy Gland Surg. 9 1685-1697

[10] Cuvelier P(2019)Active surveillance for low-risk small papillary thyroid cancer in North American countries: past, present and future (bridging the gap between North American and Asian practices) Thyroid Res. 12 586-592

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J. Clin. 68 394-424

[2] Ferlay J(2009)“Aggressive papillary” thyroid microcarcinoma Eur. Arch. Otorhinolaryngol. 266 1959-1963

[3] Soerjomataram I(2014)Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up J. Clin. Endocrinol. Metab. 99 2834-2843

[4] Siegel RL(2015)American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer Thyroid 2016 1-133

[5] Torre LA(2005)BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer J. Clin. Endocrinol. Metab. 90 6373-6379

[6] Jemal A(2016)BRAF(V600E) is correlated with recurrence of papillary thyroid microcarcinoma: a systematic review, multi-institutional primary data analysis, and meta-analysis Thyroid 26 248-255

[7] Page C(2014)BRAF Clin. Nucl. Med 39 675-679

[8] Biet A(2016) mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma Eur. J. Nucl. Med Mol. Imaging 43 1034-1039

[9] Boute P(2020)Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy Gland Surg. 9 1685-1697

[10] Cuvelier P(2019)Active surveillance for low-risk small papillary thyroid cancer in North American countries: past, present and future (bridging the gap between North American and Asian practices) Thyroid Res. 12 586-592